SLNO 53.50 Soleno Therapeutics, Inc.
| Range: | 21.3-56.81 | Vol Avg: | 553809 | Last Div: | 0 | Changes: | 3.95 |
| Beta: | -1.45 | Cap: | 2.13B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Nov 13 2014 | Empoloyees: | 33 | ||
| CUSIP: | 834203200 | CIK: | 0001484565 | ISIN: | US8342033094 | Country: | US |
| CEO: | Dr. Anish Bhatnagar M.D. | Website: | https://soleno.life | ||||
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Stock Details
SLNO 74
Soleno Therapeutics price target raised to $74 from $59 at Stifel
Dae Gon Ha·Tue Oct 01 2024
Stifel Nicolaus
SLNO 59
Stifel Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)
Dae Gon·Tue Aug 27 2024
Stifel Nicolaus
SLNO 65
Oppenheimer Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)
Leland Gershell·Tue Aug 27 2024
Oppenheimer
SLNO 93
Piper Sandler Reiterates Overweight Rating on Soleno Therapeutics Inc. (SLNO)
Yasmeen Rahimi·Thu May 23 2024
Piper Sandler
SLNO 72
Baird Starts Soleno Therapeutics Inc. (SLNO) at Outperform
Brian Skorney·Thu May 09 2024
Robert W. Baird
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow